44 Results for "

Cystic fibrosis diseases

" in MedChemExpress (MCE) Product Catalog:
Products (44)

44 Results for "Cystic fibrosis diseases" in MCE Product Catalog:

46
46 Publications Verification
Cat. No.: HY-108882B
CAS No.: 9003-98-9
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

DNase I is an enzyme that degrades DNA. DNase I is mainly produced by digestive system organs, such as the pancreas and parotid gland. Three types of DNase I are known in mammals: pancreatic type, parotid type, and pancreatico-parotid type. DNase I plays a key role in the cleavage of extracellular DNA, and is critical for limiting inflammatory responses and maintaining homeostasis. DNase I is responsible for digesting extracellular nucleoproteins, which may be essential for preventing autoimmune responses. Decreased DNase I activity may be associated with the onset and progression of systemic lupus erythematosus (SLE). DNase I (RNase & Protease free) is a molecular biology-grade DNase I purified by chromatography to remove RNase and protease .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-15448
CAS No.: 1152311-62-0
Purity:  99.85%
Synonyms: VX-661
Target:  

CFTR

Research Areas:  

Cancer

Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-145603
CAS No.: 2374124-49-7
Purity:  98.19%
Synonyms: VX-121
Target:  

CFTR Chloride Channel

Research Areas:  

Neurological Disease

Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B1153
CAS No.: 3820-67-5
Synonyms: Glafenin
Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B1153A
CAS No.: 65513-72-6
Synonyms: Glafenin hydrochloride
Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-112726
CAS No.: 1478364-68-9
Purity:  98.79%
Synonyms: BI-1467335
Target:  

VAP-1 MMP

PXS-4728A is an orally active, selective VAP-1/SSAO inhibitor with an IC50 of 5 nM and a Ki of 175 nM. PXS-4728A inhibits the expression of MMP-9. It reduces cell rolling, adhesion and migration, decreases cell infiltration levels, pro-inflammatory cytokines, chemokines and collagen deposition, and improves pulmonary function. PXS-4728A reduces the formation and progression of atherosclerotic plaques, and decreases blood lipid and blood glucose levels as well as body weight gain. PXS-4728A can be used in research related to chronic obstructive pulmonary disease, cystic fibrosis, acute pulmonary inflammation, acute lung injury, bronchiolitis obliterans syndrome, rhinovirus-exacerbated asthma, sepsis, Klebsiella pneumoniae pulmonary infection and atherosclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P4846
CAS No.: 292171-04-1
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist . Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-Y1422B
CAS No.: 9001-62-1
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

Lipase (MS grade) catalyzes the hydrolysis of triacylglycerols to release long-chain fatty acids in a site-specific manner. Lipase (MS grade) is involved in a variety of biological processes, from fat metabolism to cell signaling and inflammation, and can be used to study diseases such as pancreatic insufficiency, celiac disease and cystic fibrosis .
loading...
    loading...
Cat. No.: HY-N2388
CAS No.: 495-02-3
Auraptene is an orally active geranyloxycoumarin that can be isolated from plants in the Brassicaceae family, antibacterial, anti-pathogen, antioxidant, anti-tumor, and neuroprotective effects. Auraptene plays an important role in the treatment of various chronic diseases such as hypertension and cystic fibrosis .
loading...
    loading...
Cat. No.: HY-112624J
CAS No.: 9004-54-0
Synonyms: Dextran 4; Dextran D4; Dextran T4(MW 3200-4800)
Dextran 4,000 is a mucus rheology modifier. The dextran molecules in Dextran 4,000 can reduce the cross-link density of mucus through osmotic effects and hydrogen bond substitution, and reduce viscoelasticity and improve the mucociliary/cough clearance index by destroying the DNA-mucin network structure in mucus. Dextran 4,000 has the ability to improve the rheological properties and clearance ability of cystic fibrosis (CF) sputum, and can be used in the study of inhalation therapy or aerosol delivery of mucostatic respiratory diseases. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
loading...
    loading...
Cat. No.: HY-157261
CAS No.: 2123481-48-9
Purity:  98.68%
Research Areas:  

Endocrinology

UNC2383 is an oligonucleotide enhancer compound. UNC2383 can enhance the efficacy of antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs). UNC2383 can be used in research of diseases involving impaired oligonucleotide delivery, such as cystic fibrosis .
loading...
    loading...
Cat. No.: HY-103370
CAS No.: 66898-62-2
Purity:  99.67%
Synonyms: BA 7602-06
Target:  

Chloride Channel

Research Areas:  

Inflammation/Immunology

Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase . Talniflumate is an orally active Ca 2+-activated Cl - channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome .
loading...
    loading...
Cat. No.: HY-108464A
CAS No.: 1161-94-0
Purity:  98.1%
Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC50 of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca 2+ transport with an IC50 of 140 nM in a Ca 2+ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .
loading...
    loading...
Cat. No.: HY-109177
CAS No.: 1334546-77-8
Purity:  99.87%
Synonyms: QBW251
Target:  

CFTR

Research Areas:  

Inflammation/Immunology

Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research .
loading...
    loading...
Cat. No.: HY-135304
CAS No.: 2304852-21-7
Purity:  99.29%
PAD-IN-2 is a potent pad4 inhibitor (IC50: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis .
loading...
    loading...
Cat. No.: HY-118177
CAS No.: 1448314-31-5
Research Areas:  

Inflammation/Immunology

Neutrophil elastase inhibitor 1 is a competitive, pseudo-reversible inhibitor of human neutrophil elastase (HNE) with an IC50 of 7 nM. Neutrophil elastase inhibitor 1 also exhibits inhibitory activity against thrombin, chymotrypsin and urokinase, with IC50 values of 1.9 μM, 66 nM and 6.6 μM, respectively. Neutrophil elastase inhibitor 1 can be used in research related to acute respiratory distress syndrome, chronic obstructive pulmonary disease and other conditions .
loading...
    loading...
Cat. No.: HY-B1153R
CAS No.: 3820-67-5
Synonyms: Glafenin (Standard)
Glafenine (Standard) is the analytical standard of Glafenine. This product is intended for research and analytical applications. Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
loading...
    loading...
Cat. No.: HY-145603S
Synonyms: VX-121-d4
Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .
loading...
    loading...
Cat. No.: HY-12733
CAS No.: 1254318-44-9
AZD5248 is an orally active, selective dipeptidyl peptidase 1 (cathepsin C) inhibitor, with IC50 values of 1 nM and 17 nM against human CatC, 44 nM against human DPP1, and 67 nM against rat DPP1. It exhibits low clearance and high bioavailability in animal models. AZD5248 forms an irreversible covalent bond with the catalytic Cys234 residue of CatC, exerts reversible inhibition via its nitrile moiety, blocks CatC-dependent amyloid formation, and reduces the activation levels of neutrophil serine proteases in bone marrow and blood. AZD5248 reacts with aortic elastin aldehydes to form stable 4-imidazolinones, induces ultrastructural changes in aortic tissue, and has an α-amino acid-based backbone. AZD5248 reduces the severity of acute pancreatitis in mouse models. AZD5248 can be used in research on chronic obstructive pulmonary disease, acute pancreatitis, neurodegenerative diseases, lysosomal storage disorders, acute lung injury, cystic fibrosis, and neutrophil-mediated inflammatory diseases .
loading...
    loading...
Cat. No.: HY-179041
CAS No.: 924851-91-2
SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E2 (PGE2) and blocks the PGE2-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease .
loading...
    loading...